Hannah Dzimitrowicz, MD

Medical Instructor in the Department of Medicine
Email address hannah.dzimitrowicz@duke.edu

Education and Training

College/University
Middlebury College

Medical School
Yale University

Residency
Duke University

Education and Training

  • Residency, Internal Medicine, Duke University, 2016 - 2019
  • M.D., Yale University School of Medicine, 2016

Publications

Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.” J Clin Oncol 40, no. 8 (March 10, 2022): 807–10. https://doi.org/10.1200/JCO.21.02504.

PMID
34990219
Full Text

Hirsch, Laure, Nieves Martinez Chanza, Subrina Farah, Wanling Xie, Ronan Flippot, David A. Braun, Nityam Rathi, et al. “Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.” Jama Oncol 7, no. 12 (December 1, 2021): 1815–23. https://doi.org/10.1001/jamaoncol.2021.4544.

PMID
34673916
Full Text

Dzimitrowicz, Hannah, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, and Michael R. Harrison. “Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.” Cancer Med 10, no. 24 (December 2021): 8891–98. https://doi.org/10.1002/cam4.4407.

PMID
34751002
Full Text

Mesleh Shayeb, Akram, Danielle Urman, Nazli Dizman, Luis A. Meza, Akhilesh Sivakumar, Chun Loo Gan, Hannah Elizabeth Dzimitrowicz, et al. “Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).” In Journal of Clinical Oncology, 39:291–291. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.291.

Full Text

Hirsch, Laure, Nieves Martinez Chanza, Subrina Farah, Ronan Flippot, Nityam Rathi, Katharine Collier, Guillermo de Velasco, et al. “Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.” In Journal of Clinical Oncology, 39:310–310. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.310.

Full Text

Martinez Chanza, Nieves, Wanling Xie, Majd Issa, Hannah Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Lam, et al. “Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2020-000538.

PMID
32217762
Full Text

Dzimitrowicz, Hannah Elizabeth, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, and Michael Roger Harrison. “Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Chanza, Nieves Martinez, Wanling Xie, Majd Issa, Hannah Elizabeth Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Tat Lam, et al. “Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Martínez Chanzá, Nieves, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M. Geynisman, Archana Balakrishnan, et al. “Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.” Lancet Oncol 20, no. 4 (April 2019): 581–90. https://doi.org/10.1016/S1470-2045(18)30907-0.

PMID
30827746
Full Text

Pages